European Archives - Page 968 of 1157 - European Medical Journal

Asceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor

Lausanne, Switzerland, April 06, 2017 – Asceneuron SA, an emerging leader in the development of innovative small molecules for neurodegenerative diseases…

RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma

Tel-Aviv, Israel, April 04, 2017 – RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty…

Australia’s Bionic Vision Technologies Raises US$18 Million (AU$23.5 M) to Develop ‘Bionic Eye’ for Global Markets

Melbourne, Australia, April 03, 2017 – Retinal implant innovator Bionic Vision Technologies (BVT) today announced it had raised US $18 million…

Imanova Receives £1M Award from the MRC To Develop Early Markers of Dementia –The MIND-MAPS Study

London, UK, April 03, 2017 – Following a £0.5m Medical Research Council (MRC) grant to implement new Positron Emission Tomography (PET) imaging tracers…

ELCC 2017: Latest News in Lung Cancer

Geneva, Switzerland, May 5-8 2017 – Around 2,000 delegates from across Europe and worldwide will learn about the latest practice-changing science in the…

Low Vitamin D Levels Linked to Ulcerative Colitis Relapse

CLINICAL relapse risk amongst individuals with ulcerative colitis (UC) more common if the levels of vitamin D in the blood are lower than required…

Connection Uncovered Between Gut Bacteria and Patient Behaviour

A POTENTIAL link has been discerned between gut bacteria and behaviour in patients with irritable bowel syndrome (IBS), a common gastrointestinal…

This March, EMJ Supports

This March, EMJ has proudly showcased its support for an assortment of medical campaigns including: Ovarian Cancer Awareness Month, World Kidney Day…

Revolutionising Digital Healthcare within the National Health Service

The National Health Service (NHS) in the UK is set to introduce major changes to the NHS Choices website in the following months, after an increased…

Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

Krakow, Poland / Berlin, Germany, March 28, 2017 – Selvita S.A. (WSE:SLV), and Berlin-Chemie Menarini, a company of the Menarini Group, announced today…